<DOC>
	<DOCNO>NCT00002212</DOCNO>
	<brief_summary>The purpose study see safe effective give Targretin capsule patient AIDS-related Kaposi 's sarcoma ( KS ) .</brief_summary>
	<brief_title>A Study Targretin Capsules Patients With AIDS-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description>This multicenter , open-label study evaluate safety efficacy Targretin capsule patient AIDS-related KS . NOTE : The daily dose may reduce necessary toxicity management .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<criteria>Inclusion Criteria Patients must : Serum HIV antibody positive ELISA . KS document biopsy ( repeat biopsy require entry KS previously confirm histologically histopathology report review ) . A minimum 6 mucocutaneous KS lesion , include least 3 raise lesion , present least 30 day long dimension least 10mm , receive prior local topical therapy within 60 day study entry . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Concurrent , serious , uncontrolled infection include , limited : Mycobacterium avium intracellulare mycobacterium infection ; Pneumocystis carinii pneumonia ; CMV retinitis colitis ; Toxoplasma brain abscess ; Cryptococcal meningitis . Serious intercurrent illness infection would interfere ability patient carry treatment program . Known allergy sensitivity retinoid class drug . Concurrent Medication : Excluded : Local topical therapy , limited , Vitamin A , tretinoin ( alltransretinoic acid ) , retinoid class drug , intralesional ( injection ) therapy KS indicator lesion . Systemic anticancer chemotherapy , systemic anticancer hormonal therapy , and/or systemic anticancer immunotherapy . Systemic use retinoid class drug , betacarotene compound , Vitamin A dose great 15,000 IU ( 5,000 mcg ) per day ( equivalent approximately 3 time RDA ) indication . Human chorionic gonadotropin . Concurrent Treatment : Excluded : Radiotherapy , cryotherapy , photodynamic therapy , and/or laser therapy KS indicator lesion . Prior Medication : Excluded : Systemic treatment KS within 30 day study entry . Systemic treatment either Vitamin A dose great 15,000 IU ( 5,000 mcg ) per day ( equivalent approximately 3 time RDA ) retinoid class drug indication within 30 day study entry . Previous local topical therapy KS indicator lesion , limited , Vitamin A , tretinoin ( alltransretinoic acid ) , retinoid class drug , intralesional ( injection ) therapy within 60 day study entry . Prior Treatment : Excluded : Radiotherapy , cryotherapy , photodynamic therapy and/or laser therapy within 60 day study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1999</verification_date>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Anticarcinogenic Agents</keyword>
</DOC>